Delcath Systems, Inc.
DCTHHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The $503.5M market capitalization puts DCTH squarely in small-cap range for its industry. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Market Cap
$503.5M
Beta
0.60
P/E (TTM)
1451.00
P/E (Fwd)
322.44
EPS (TTM)
$0.01
EPS (Fwd)
$0.04
ROE
0.5%
ROA
-0.9%
Cash
$95.9M
Total Debt
$2.5M
Free CF
$18.1M
52W Change
45.3%
Annual Financials
Cash vs Debt
Where DCTH stands vs its 150-day and 200-day moving averages
As of the October 5, 2026 close, DCTH finished 21.04% above its 150-day moving average ($12.50) and 27.46% above its 200-day moving average ($11.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DCTH overbought or oversold?
At the October 5, 2026 close, DCTH's RSI(14) was 28.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Delcath Systems, Inc. holds $95.9M in cash against $2.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $18.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 0.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $2.7M (2022) to $85.2M (2025), reflecting a 3035% increase over the period.
The relatively low beta of 0.60 suggests DCTH is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, DCTH has financial flexibility that may help navigate uncertain periods. At over 50x earnings, DCTH carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Delcath Systems, Inc.'s trajectory.